Navigation Links
Aeterna Zentaris to Announce Second Quarter 2010 Financial and Operating Results on August 12, 2010
Date:8/4/2010

QUÉBEC CITY, Aug. 4 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, will announce its second quarter 2010 financial and operating results before market open on Thursday, August 12, 2010. The Company will host a conference call and webcast to discuss these results later that same day at 1:30 p.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: in Canada, 514-807-9895 or 647-427-7451, outside Canada, 888-231-8191. A replay of the webcast will also be available on the Company's website for a period of 30 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrinology. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference 2010 on August 12
2. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
3. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
4. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
5. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
6. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
7. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
8. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
9. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
10. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
11. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Oxis Biotech, Inc. (OXIS), ... OXIS, OXI.PA, announced today that Cassian Yee , ... Cancer Medicine at the University of Texas MD Anderson ... is also Professor, Department of Immunology, Division of Cancer ... Cancer Immunology Research at the University of Texas MD ...
(Date:5/6/2015)... Portland, OR (PRWEB) May 06, 2015 ... executive search and growth strategy for the specialty pharmacy ... Sponser of the 2015 Armada Specialty Pharmacy Summit. The ... Wynn Hotel in Las Vegas and is the largest ... people will be in attendance, from pharmacy providers, pharma/biotech ...
(Date:5/5/2015)... May 5, 2015  23andMe, Inc., the leading personal ... Lupus Research Study in collaboration with Pfizer Inc. ... lupus erythematosus, more commonly known as lupus, into the ... The effort is also in collaboration with the Lupus ... in May. Approximately 1.5 million people in ...
(Date:5/5/2015)... , May 5, 2015  Tikcro Technologies ... was approved to continue trading on OTCQB  Marketplace, ... OTCQB Marketplace allows for a continuous public ... Investors can have real-time quotes and market information ... The OTCQB Marketplace includes U.S. and international ...
Breaking Biology Technology:Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2
... 23 Pharmaceutical and biotech partners tasked with cutting costs and improving ... What are the implications of the current economic ... can I harness the knowledge of all employees to improve processes cross-functionally? ... methodologies do I use to show the revenue of quality instead of ...
... WYE ) announced today that it will ... Stock, par value $2.50 per share (the "Convertible Preferred ... As of April 22, 2009, there were 8,896 ... each share of Convertible Preferred Stock is $60.08, which ...
... Provide Proprietary Protein and Small Molecule Products for ... Stem (iPS) CellsLA JOLLA, Calif. and BOSTON, April ... and Stemgent, Inc. ... one-of-a-kind program to provide pharmaceutical and biotechnology companies ...
Cached Biology Technology:Cost-Cutting Plus Value-Add Defines Quality's Role in a Recession 2Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 2Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 3Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 4Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 5Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 2Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 3Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 4
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... in the open-access journal PLoS Biology, streamlines the computation ... genome that influence a particular physical trait, or phenotype. ... Joshua M. Akey, and Leonid Kruglyak, researchers have a ... the genomic elements that produce specific traits. , In ...
... gene therapy can promote the growth of new "insulation" around ... new study shows. The treatment, which mimics the activity of ... and electrical conduction from the brain to the leg muscles. ... spinal cord injury in humans. The study was funded in ...
... results of a study conducted at Johns Hopkins show that ... attacks, or myocardial infarction, in pigs. In just two months, ... into the animal's damaged heart restored heart function and repaired ... The Hopkins findings, first presented last fall at the 2004 ...
Cached Biology News:Improved statistical tools reveal many linked loci 2Combination therapy leads to partial recovery from spinal cord injury in rats 2Combination therapy leads to partial recovery from spinal cord injury in rats 3Stem cell therapy successfully treats heart attack in animals 2
Mol wt: average mol wt12,360.96 Da by calculation...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... Adaptor encodes a T7 promoter, lac ... translation initation codon and an N-terminal GST•Tag ... reported to enhance the production and in ... partners. The GST•Tag is a multi-purpose tag ...
A cost-effective serum for general cell growth requirements. All serum is collected from calves aged 10 days old or less....
Biology Products: